{"id":1309,"date":"2022-06-02T12:45:30","date_gmt":"2022-06-02T10:45:30","guid":{"rendered":"https:\/\/salvia.de\/?p=1309"},"modified":"2022-06-02T13:17:13","modified_gmt":"2022-06-02T11:17:13","slug":"biontech-se-concluded-the-annual-general-meeting-2022","status":"publish","type":"post","link":"https:\/\/salvia.de\/en\/biontech-se-concluded-the-annual-general-meeting-2022\/","title":{"rendered":"BioNTech SE concluded the Annual General Meeting 2022"},"content":{"rendered":"<p><strong>01.06.2022 &#8211; Helmut Jeggle <span class=\"break-words\"><span dir=\"ltr\">was reappointed as Chairman of the Supervisory Board<\/span><\/span><\/strong><\/p>\n<p>In addition, <strong>Prof. Dr. Anja Morawietz<\/strong> and <strong>Prof. Dr. Rudolf Staudigl<\/strong> will complement the Supervisory Board as additional members, reflecting BioNTech\u2019s growth with additional expertise in finance, governance and international markets. All three members will serve in their roles until the AGM 2026.<\/p>\n<p>In addition, the shareholders passed the proposal of the Management Board and Supervisory Board to pay a special cash dividend of \u20ac2.00 per ordinary share (incl. those held in the form of ADSs) in addition to the repurchase program of BioNTech shares in the amount of up to $1.5 billion over the next two years.<\/p>\n<p>\u201cOver the past two years, BioNTech has developed into a fully integrated biotech company with a diversified clinical pipeline, including several late-staged product candidates. We want our shareholders to participate in our strong 2021 performance via a special cash dividend and a share repurchase program. This is in line with BioNTech\u2019s capital allocation strategy and the company\u2019s commitment to delivering shareholder value,\u201d <strong>said Helmut Jeggle, Chairman of the Supervisory Board of BioNTech<\/strong>. \u201cWith Prof. Dr. Anja Morawietz and Prof. Dr. Rudolf Staudigl, we are gaining further expertise in finance, governance and international markets, which will complement the existing skillset of the Board. I am grateful for the<br \/>\nopportunity to continue to serve this company as Chairman of the Supervisory Board.\u201d<\/p>\n<p>Read more: <a href=\"https:\/\/salvia.de\/en\/2022-06-01_voting-results-from-biontechs-annual-general-meeting-2022\/\">Download Press release<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>01.06.2022 &#8211; Helmut Jeggle was reappointed as Chairman of the Supervisory Board In addition, Prof. Dr. Anja Morawietz and Prof. Dr. Rudolf Staudigl will complement the Supervisory Board as additional members, reflecting BioNTech\u2019s growth with additional expertise in finance, governance and international markets. All three members will serve in their roles until the AGM 2026. [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[30],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>BioNTech SE concluded the Annual General Meeting 2022 - Salvia GmbH<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/salvia.de\/en\/biontech-se-concluded-the-annual-general-meeting-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioNTech SE concluded the Annual General Meeting 2022 - Salvia GmbH\" \/>\n<meta property=\"og:description\" content=\"01.06.2022 &#8211; Helmut Jeggle was reappointed as Chairman of the Supervisory Board In addition, Prof. Dr. Anja Morawietz and Prof. Dr. Rudolf Staudigl will complement the Supervisory Board as additional members, reflecting BioNTech\u2019s growth with additional expertise in finance, governance and international markets. All three members will serve in their roles until the AGM 2026. [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/salvia.de\/en\/biontech-se-concluded-the-annual-general-meeting-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Salvia GmbH\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-02T10:45:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-06-02T11:17:13+00:00\" \/>\n<meta name=\"author\" content=\"Salvia GmbH\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Salvia GmbH\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/salvia.de\/en\/biontech-se-concluded-the-annual-general-meeting-2022\/\",\"url\":\"https:\/\/salvia.de\/en\/biontech-se-concluded-the-annual-general-meeting-2022\/\",\"name\":\"BioNTech SE concluded the Annual General Meeting 2022 - Salvia GmbH\",\"isPartOf\":{\"@id\":\"https:\/\/salvia.de\/#website\"},\"datePublished\":\"2022-06-02T10:45:30+00:00\",\"dateModified\":\"2022-06-02T11:17:13+00:00\",\"author\":{\"@id\":\"https:\/\/salvia.de\/#\/schema\/person\/3af210793101a618e4cab377f5d7585c\"},\"breadcrumb\":{\"@id\":\"https:\/\/salvia.de\/en\/biontech-se-concluded-the-annual-general-meeting-2022\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/salvia.de\/en\/biontech-se-concluded-the-annual-general-meeting-2022\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/salvia.de\/en\/biontech-se-concluded-the-annual-general-meeting-2022\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/salvia.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioNTech SE concluded the Annual General Meeting 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/salvia.de\/#website\",\"url\":\"https:\/\/salvia.de\/\",\"name\":\"Salvia GmbH\",\"description\":\"Wir unterst\u00fctzen heute innovative Unternehmen von morgen mit Kapital, Know-how und Netzwerk.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/salvia.de\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/salvia.de\/#\/schema\/person\/3af210793101a618e4cab377f5d7585c\",\"name\":\"Salvia GmbH\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/salvia.de\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d76f3c6a335d5aadaa80deb8f13de078?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d76f3c6a335d5aadaa80deb8f13de078?s=96&d=mm&r=g\",\"caption\":\"Salvia GmbH\"},\"url\":\"https:\/\/salvia.de\/en\/author\/salvia-gmbh\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioNTech SE concluded the Annual General Meeting 2022 - Salvia GmbH","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/salvia.de\/en\/biontech-se-concluded-the-annual-general-meeting-2022\/","og_locale":"en_US","og_type":"article","og_title":"BioNTech SE concluded the Annual General Meeting 2022 - Salvia GmbH","og_description":"01.06.2022 &#8211; Helmut Jeggle was reappointed as Chairman of the Supervisory Board In addition, Prof. Dr. Anja Morawietz and Prof. Dr. Rudolf Staudigl will complement the Supervisory Board as additional members, reflecting BioNTech\u2019s growth with additional expertise in finance, governance and international markets. All three members will serve in their roles until the AGM 2026. [&hellip;]","og_url":"https:\/\/salvia.de\/en\/biontech-se-concluded-the-annual-general-meeting-2022\/","og_site_name":"Salvia GmbH","article_published_time":"2022-06-02T10:45:30+00:00","article_modified_time":"2022-06-02T11:17:13+00:00","author":"Salvia GmbH","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Salvia GmbH","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/salvia.de\/en\/biontech-se-concluded-the-annual-general-meeting-2022\/","url":"https:\/\/salvia.de\/en\/biontech-se-concluded-the-annual-general-meeting-2022\/","name":"BioNTech SE concluded the Annual General Meeting 2022 - Salvia GmbH","isPartOf":{"@id":"https:\/\/salvia.de\/#website"},"datePublished":"2022-06-02T10:45:30+00:00","dateModified":"2022-06-02T11:17:13+00:00","author":{"@id":"https:\/\/salvia.de\/#\/schema\/person\/3af210793101a618e4cab377f5d7585c"},"breadcrumb":{"@id":"https:\/\/salvia.de\/en\/biontech-se-concluded-the-annual-general-meeting-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/salvia.de\/en\/biontech-se-concluded-the-annual-general-meeting-2022\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/salvia.de\/en\/biontech-se-concluded-the-annual-general-meeting-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/salvia.de\/en\/"},{"@type":"ListItem","position":2,"name":"BioNTech SE concluded the Annual General Meeting 2022"}]},{"@type":"WebSite","@id":"https:\/\/salvia.de\/#website","url":"https:\/\/salvia.de\/","name":"Salvia GmbH","description":"Wir unterst\u00fctzen heute innovative Unternehmen von morgen mit Kapital, Know-how und Netzwerk.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/salvia.de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/salvia.de\/#\/schema\/person\/3af210793101a618e4cab377f5d7585c","name":"Salvia GmbH","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/salvia.de\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d76f3c6a335d5aadaa80deb8f13de078?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d76f3c6a335d5aadaa80deb8f13de078?s=96&d=mm&r=g","caption":"Salvia GmbH"},"url":"https:\/\/salvia.de\/en\/author\/salvia-gmbh\/"}]}},"_links":{"self":[{"href":"https:\/\/salvia.de\/en\/wp-json\/wp\/v2\/posts\/1309"}],"collection":[{"href":"https:\/\/salvia.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/salvia.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/salvia.de\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/salvia.de\/en\/wp-json\/wp\/v2\/comments?post=1309"}],"version-history":[{"count":1,"href":"https:\/\/salvia.de\/en\/wp-json\/wp\/v2\/posts\/1309\/revisions"}],"predecessor-version":[{"id":1310,"href":"https:\/\/salvia.de\/en\/wp-json\/wp\/v2\/posts\/1309\/revisions\/1310"}],"wp:attachment":[{"href":"https:\/\/salvia.de\/en\/wp-json\/wp\/v2\/media?parent=1309"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/salvia.de\/en\/wp-json\/wp\/v2\/categories?post=1309"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/salvia.de\/en\/wp-json\/wp\/v2\/tags?post=1309"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}